BACKGROUND: Performance measures that emphasize only a treat-to-target approach may motivate overtreatment with high-dose statins, potentially leading to adverse events and unnecessary costs. We developed a clinical action performance measure for lipid management in patients with diabetes mellitus that is designed to encourage appropriate treatment with moderate-dose statins while minimizing overtreatment. METHODS AND RESULTS: We examined data from July 2010 to June 2011 for 964 818 active Veterans Affairs primary care patients ≥18 years of age with diabetes mellitus. We defined 3 conditions as successfully meeting the clinical action measure for patients 50 to 75 years old: (1) having a low-density lipoprotein (LDL) <100 mg/dL, (2) taking a moderate-dose statin regardless of LDL level or measurement, or (3) receiving appropriate clinical action (starting, switching, or intensifying statin therapy) if LDL is ≥100 mg/dL. We examined possible overtreatment for patients ≥18 years of age by examining the proportion of patients without ischemic heart disease who were on a high-dose statin. We then examined variability in measure attainment across 881 facilities using 2-level hierarchical multivariable logistic models. Of 668 209 patients with diabetes mellitus who were 50 to 75 years of age, 84.6% passed the clinical action measure: 67.2% with LDL <100 mg/dL, 13.0% with LDL ≥100 mg/dL and either on a moderate-dose statin (7.5%) or with appropriate clinical action (5.5%), and 4.4% with no index LDL on at least a moderate-dose statin. Of the entire cohort ≥18 years of age, 13.7% were potentially overtreated. Facilities with higher rates of meeting the current threshold measure (LDL <100 mg/dL) had higher rates of potential overtreatment (P<0.001). CONCLUSIONS: Use of a performance measure that credits appropriate clinical action indicates that almost 85% of diabetic veterans 50 to 75 years of age are receiving appropriate dyslipidemia management. However, many patients are potentially overtreated with high-dose statins.
BACKGROUND: Performance measures that emphasize only a treat-to-target approach may motivate overtreatment with high-dose statins, potentially leading to adverse events and unnecessary costs. We developed a clinical action performance measure for lipid management in patients with diabetes mellitus that is designed to encourage appropriate treatment with moderate-dose statins while minimizing overtreatment. METHODS AND RESULTS: We examined data from July 2010 to June 2011 for 964 818 active Veterans Affairs primary care patients ≥18 years of age with diabetes mellitus. We defined 3 conditions as successfully meeting the clinical action measure for patients 50 to 75 years old: (1) having a low-density lipoprotein (LDL) <100 mg/dL, (2) taking a moderate-dose statin regardless of LDL level or measurement, or (3) receiving appropriate clinical action (starting, switching, or intensifying statin therapy) if LDL is ≥100 mg/dL. We examined possible overtreatment for patients ≥18 years of age by examining the proportion of patients without ischemic heart disease who were on a high-dose statin. We then examined variability in measure attainment across 881 facilities using 2-level hierarchical multivariable logistic models. Of 668 209 patients with diabetes mellitus who were 50 to 75 years of age, 84.6% passed the clinical action measure: 67.2% with LDL <100 mg/dL, 13.0% with LDL ≥100 mg/dL and either on a moderate-dose statin (7.5%) or with appropriate clinical action (5.5%), and 4.4% with no index LDL on at least a moderate-dose statin. Of the entire cohort ≥18 years of age, 13.7% were potentially overtreated. Facilities with higher rates of meeting the current threshold measure (LDL <100 mg/dL) had higher rates of potential overtreatment (P<0.001). CONCLUSIONS: Use of a performance measure that credits appropriate clinical action indicates that almost 85% of diabetic veterans 50 to 75 years of age are receiving appropriate dyslipidemia management. However, many patients are potentially overtreated with high-dose statins.
Authors: Christie M Ballantyne; Alberto Corsini; Michael H Davidson; Hallvard Holdaas; Terry A Jacobson; Eran Leitersdorf; Winfried März; John P D Reckless; Evan A Stein Journal: Arch Intern Med Date: 2003-03-10
Authors: Eve A Kerr; Dylan M Smith; Mary M Hogan; Timothy P Hofer; Sarah L Krein; Martin Bermann; Rodney A Hayward Journal: Med Care Date: 2003-10 Impact factor: 2.983
Authors: Paul S Phillips; Richard H Haas; Sergei Bannykh; Stephanie Hathaway; Nancy L Gray; Bruce J Kimura; Georgirene D Vladutiu; John D F England Journal: Ann Intern Med Date: 2002-10-01 Impact factor: 25.391
Authors: Yashashwi Pokharel; Julia M Akeroyd; David J Ramsey; Ravi S Hira; Vijay Nambi; Tina Shah; LeChauncy D Woodard; David E Winchester; Christie M Ballantyne; Laura A Petersen; Salim S Virani Journal: Clin Cardiol Date: 2016-04-05 Impact factor: 2.882
Authors: Sameer D Saini; Adam A Powell; Jason A Dominitz; Deborah A Fisher; Joseph Francis; Linda Kinsinger; Kathleen S Pittman; Philip Schoenfeld; Stephanie E Moser; Sandeep Vijan; Eve A Kerr Journal: J Gen Intern Med Date: 2016-04 Impact factor: 5.128
Authors: Hasan Rehman; Julia M Akeroyd; David Ramsey; Sarah T Ahmed; Anwar T Merchant; Sankar D Navaneethan; Laura A Petersen; Salim S Virani Journal: Clin Cardiol Date: 2017-08-25 Impact factor: 2.882
Authors: Laura J Damschroder; Claire H Robinson; Joseph Francis; Douglas R Bentley; Sarah L Krein; Ann-Marie Rosland; Timothy P Hofer; Eve A Kerr Journal: J Gen Intern Med Date: 2014-12 Impact factor: 5.128
Authors: Varsha G Vimalananda; Donald R Miller; Timothy P Hofer; Robert G Holleman; Mandi L Klamerus; Eve A Kerr Journal: J Gen Intern Med Date: 2013-07 Impact factor: 5.128